Metabolism: clinical and experimentalAnimalsObesityRatsGlucagon-Like Peptide-1 Receptor AgonistsMale
A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.
Emily F Ashlaw, Clinton T Elfers, Kylie S Chichura, Isabella Chavez Miranda, Aelish McGivney, Oleg G Chepurny, George G Holz, Ginger Mullins, Laura J den Hartigh, Yongjun Liu, Christian L Roth, Robert P Doyle
Published: 202610.1016/j.metabol.2025.156414
Abstract
Obesity and its sequelae cause significant morbidity and mortality worldwide. Current glucagon-like peptide-1 (GLP-1) receptor agonist-based treatments have significant side-effects associated with high rates of treatment discontinuation. Such concer…
Preview only. Read the full abstract at the source